Tolerance after portal venous immunization is enhanced by anti-IFN-gamma and is maintained only with persistence of antigen.
Gorczynski
R M
RM
MRC Liver Program Project Group, Toronto General Hospital, Ontario, Canada.
Chen
Z
Z
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D016207:Cytokines / Q000096:biosynthesis*; D015870:Gene Expression; D007108:Immune Tolerance; D007165:Immunosuppression Therapy / Q000379:methods*; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology*; D016753:Interleukin-10 / Q000096:biosynthesis; D007376:Interleukin-2 / Q000096:biosynthesis; D015847:Interleukin-4 / Q000096:biosynthesis; D017710:Lymphocyte Transfusion; D051379:Mice; D008809:Mice, Inbred C3H; D008815:Mice, Inbred Strains; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000032:analysis / Q000096:biosynthesis; D016038:Skin Transplantation / Q000276:immunology*; D013045:Species Specificity; D013154:Spleen / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D016207:Cytokines; D007376:Interleukin-2; D012333:RNA, Messenger; D016753:Interleukin-10; D015847:Interleukin-4; D007371:Interferon-gamma